Merck to acquire Imago BioSciences to expand blood disorder drugs portfolio
Pharma giant Merck will acquire Imago BioSciences, a Nasdaq-listed clinical stage biopharmaceutical company, for a price of $36 per share in cash, which translates to a total equity value of around $1.35bn. The acquisition is expected to expand Merck’s blood disorder drugs portfolio. Imago BioSciences is focused on developing new drugs for the treatment of […]